FDA warns of heart risk with HIV drug combination

October 21, 2010

(AP) -- The Food and Drug Administration is warning HIV patients not to combine two widely used antiviral drugs because they can cause dangerous heart rhythms.

The agency says the combination of Roche's Invirase and Abbott Laboratories' Norvir can trigger irregular heartbeats, leading to fainting, lightheadedness and even death. The FDA is requiring the companies to add information about the risk to their drugs' warning labels and to distribute pamphlets to patients.

Patients with HIV generally cycle through combinations of medicines to control the virus, which attacks the immune system.

The FDA approved Invirase in 1995 to lower HIV levels in the blood. It is often combined with Norvir to improve its effectiveness.

More than 1.1 million people in the U.S. have , according to the Centers for Disease Control and Prevention.

shares

Related Stories

Recommended for you

Overcoming Opioids: When pills are a hospital's last resort

May 2, 2017

A car crash shattered Stuart Anders' thigh, leaving pieces of bone sticking through his skin. Yet Anders begged emergency room doctors not to give him powerful opioid painkillers—he'd been addicted once before and panicked ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.